NeuroSense Therapeutics (NRSN) Operating Expenses (2021 - 2024)
NeuroSense Therapeutics (NRSN) posted Operating Expenses of $9.6 million for Q4 2024, up 200.54% sequentially from -$9.6 million in Q3 2024, and down 16.2% YoY from $11.5 million in Q1 2024.
NeuroSense Therapeutics (NRSN) Operating Expenses (2021 - 2024) Analysis & Trends
NeuroSense Therapeutics has reported Operating Expenses for 4 years, with the latest figure at $9.6 million in Q4 2024.
- Quarterly Operating Expenses fell 16.2% year-over-year to $9.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $52000.0 (down 96.52% YoY) and the FY2025 annual result came in at $1.8 million, down 9.52% from the prior year.
- Operating Expenses improved to $9.6 million in Q4 2024 per NRSN's latest filing, from -$9.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $11.5 million in Q4 2023 and troughed at -$9.7 million in Q3 2022.
- A 4-year average of $90500.0 and a median of -$1.5 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses soared 3114.7% in 2023, then sank 264.55% in 2024.
- Over 4 years, Operating Expenses stood at $3.7 million in 2021, then plunged by 110.17% to -$381000.0 in 2022, then soared by 3114.7% to $11.5 million in 2023, then declined by 16.2% to $9.6 million in 2024.
- According to Business Quant data, Operating Expenses over the past three periods registered $9.6 million, -$9.6 million, and $4.4 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 541.02 Mn |
| 10 | NeuroSense Therapeutics | 9.94 Mn | 9.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 9.63 Mn |
| Sep 30, 2024 | -9.57 Mn |
| Jun 30, 2024 | 4.44 Mn |
| Mar 31, 2024 | -2.99 Mn |
| Dec 31, 2023 | 11.49 Mn |
| Sep 30, 2023 | -2.63 Mn |
| Jun 30, 2023 | -3.37 Mn |
| Mar 31, 2023 | -2.99 Mn |
| Dec 31, 2022 | -381,000.00 |
| Sep 30, 2022 | -9.65 Mn |
| Jun 30, 2022 | 2.74 Mn |
| Mar 31, 2022 | -3.26 Mn |
| Dec 31, 2021 | 3.75 Mn |
| Jun 30, 2021 | 4.08 Mn |